Company intelligence / Profile preview
Sichuan Yuanda Shuyang Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Sichuan Yuanda Shuyang Pharmaceutical is a leading Chinese blood product manufacturer with approved plasma-derived products (albumin, immunoglobulins, coagulation factors) and an expanding pipeline in recombinant proteins and monoclonal antibodies. KN057 (TFPI monoclonal antibody) for hemophilia A has received FDA Orphan Drug Designation; other pipeline assets include biosimilar omalizumab and prothrombin complex concentrates, with most programs already commercialized in China or under active late-stage review[2][3][5][7].
- Therapeutic areas
- HematologyInfectious DiseasesDermatology
- Modalities
- BiologicMonoclonal antibodyImmunoglobulinEnzymeNon-recombinant coagulation factorProtein
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sichuan Yuanda Shuyang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Yuanda Shuyang Pharmaceutical.